BM
Therapeutic Areas
Vetoquinol Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Felpreva (tigolaner/emodepside/praziquantel) | Broad-spectrum parasitic treatment for cats | Approved |
| Osphos (clodronate injection) | Navicular syndrome/lameness in horses | Approved |
| Imrestor (cabergoline) | Inhibition of lactation in cows (agalactia) | Approved |
| Zeleris (meloxicam) | Pain and inflammation in dogs and cats | Approved |
| Aivlosin (tylvalosin) | Respiratory and enteric diseases in swine and poultry | Approved |
| Novel Dermatology Product | Atopic dermatitis in dogs | Development |
Leadership Team at Vetoquinol
MF
Matthieu Frechin
Chairman of the Board of Directors
TG
Thierry Geffroy
Chief Executive Officer (CEO)
LR
Ludovic Roux
Deputy Chief Executive Officer, in charge of Operations
SM
Stéphane Martinot
Chief Financial Officer (CFO)
PD
Pierre de Lageneste
Deputy CEO, Director of the Industry Division
JG
Jean-François Guilmard
Director of the Commercial Division
DI
Dr. Isabelle Lesponne
Director of Research & Development
ED
Emmanuel de La Farge
Director of Corporate Development and Strategy
BH
Benoit Huyghe
Director of the Companion Animal Business Unit
LD
Laurent de Carné
Director of the Livestock Business Unit